Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-B-dependent activation of the urokinase plasminogen activator system

British Journal of Cancer

Volumn 100, Issue 10, 2009, Pages 1589-1602

  Killeen, S D ^a   Wang, J H ^a   Andrews, E J ^a   Redmond, H P ^a  

^a Department of Medicine National University of Ireland Cork   (Ireland)

Author keywords

Extracellular matrix; Lipopolysaccharide; Perioperative metastatic tumour growth; Urokinase plasminogen activator system

Indexed keywords

AMILORIDE; BACTERIUM LIPOPOLYSACCHARIDE; ENZYME ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; RECEPTOR ANTIBODY; SN 50; TOLL LIKE RECEPTOR 4; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CELL ADHESION; CELL INVASION; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR UPREGULATION; UPREGULATION;

AMILORIDE; ANTIBODIES; BACTERIAL TOXINS; CACO-2 CELLS; CARCINOMA; CELL ADHESION; CELL MOVEMENT; COLORECTAL NEOPLASMS; HUMANS; LIPOPOLYSACCHARIDES; NEOPLASM INVASIVENESS; NF-KAPPA B; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TOLL-LIKE RECEPTOR 4; TUMOR CELLS, CULTURED; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 66149129910     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604942     Document Type: Article

References (44)

1. Aggarwal B (2004) Nuclear factor-κB: the enemy within. Cancer Cell 6: 203-208
2. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ (2000) Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 1: 100-110
3. Andrews EJ, Wang JH, Winter DC, Lang WE, Redmond HP (2001) Tumor cell adhesion to endothelial cells is increased by endotoxin via an upregulation of beta-1 integrin expression. J Surg Res 97: 14-19
4. Böcker U, Yezerskyy O, Feick P, Manigold T, Panja A, Kalina U, Herweck F, Rossol S, Singer MV (2003) Responsiveness of intestinal epithelial cell lines to lipopolysaccharide is correlated with Toll-like receptor 4 but not Toll-like receptor 2 or CD14 expression. Int J Colorectal Dis 18: 25-32
5. Coffey JC, Wang JH, Bouchier-Hayes D, Cotter TG, Redmond HP (2006) The targeting of phosphoinositide-3 kinase attenuates pulmonary metastatic tumor growth following laparotomy. Ann Surg 243(2): 250-256
6. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-866
7. Cubellis MV, Wun TC, Blasi F (1990) Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9: 1079-1085
8. Da Costa ML, Redmond HP, Boucher-Hayes DJ (1998) The effect of laparotomy and laparoscopy on the establishment of spontaneous tumour metastases. Surgery 124: 516-526
9. Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, Muller Berghaus G, Collen D (1988) Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 263: 15454-15461
10. Degryse B, Orlando S, Resnati M, Rabbani SA, Blasi F (2001) Urokinase/ urokinase receptor and vitronectin/alpha (v)-beta (3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene 20: 2032-2043
11. Duffy MJ (2002) Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 48: 1194-1197
12. Dumler I, Weis A, Mayboroda OA, Maasch C, Jerke U, Haller H, Gulba DC (1998) The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem 273: 315-321
13. Ennis HL, Lubin M (1964) Cycloheximide: aspects of inhibition of protein synthesis in mammalian cells. Science 146: 1474-1476
14. Ertongur S, Lang S, Mack B, Wosikowski K, Muehlenweg B, Gires O (2004) Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer 110: 815-824
15. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH, Abreu MT (2007) Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133: 1869-1881
16. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW (1994) Urokinase receptor and colorectal cancer survival. Lancet 344: 401-402
17. Gibson PR, Rosella O, Wilson AJ, Mariadason JM, Rickard K, Byron K, Barkla DH (1999) Colonic epithelial cell activation and the paradoxical effects of butyrate. Carcinogenesis 20: 539-544
18. Harmey JH, Bucana CD, Lui W, Byrne AM, McDonnell S, Lynch C, Bouchar-Hayes D, Dong Z (2002) Lipopolysaccharide induced metastatic growth is associated with increased angiogenesis, vascular permenability and tumour cell invasion. Int J Cancer 101: 415-422
19. Hart IR, Saini A (1992) Biology of tumor metastasis. Lancet 339: 1453-1457
20. Harvey SR, Sait SN, Xu Y, Bailey JL, Penetrante RM, Markus G (1999) Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization. Am J Pathol 155: 1115-1120
21. Herszényi L, István G, Cardin R, De Paoli M, Plebani M, Tulassay Z, Farinati F (2008) Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers. Eur J Cancer Prev 17(5): 438-445
22. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT (1996) The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 224: 344-353
23. Li TS, Kaneda Y, Ueda K (2001) The influence of tumour resection on angiostatin levels and tumour growth - an experimental study on tumour bearing mice. Eur J Cancer 37: 2283-2288
24. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M (2004) Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNF-alpha to TRAIL-mediated tumor regression. Cancer Cell 6: 297-305
25. Manthey CL, Brandes ME, Perera PY, Vogel SN (1992) Taxol increases steady-state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages. J Immunol 149(7): 2459-2465
26. Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352: 476-487
27. Nguyen DH, Hussaini IM, Gonias SL (1998) Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 273: 8502-8507
28. Perera PY, Mayadas TN, Takeuchi O, Akira S, Zaks-Zilberman M, Goyert SM, Vogel SN (2001) CD11b/CD18 acts in concert with CD14 and Tolllike receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J Immunol 166: 574-579
29. Pidgeon GP, Harmey JH, Kay E, Da Costa M, Redmond HP, Bouchier-Hayes DJ (1999) The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer 81: 1311-1317
30. Pollanen J, Stephens R, Salonen EM, Vaheri A (1988) Proteolytic mechanisms operating at the surface of invasive cells. Adv Exp Med Biol 233: 187-199
31. Pollanen J, Vaheri A, Tapiovaara H, Riley E, Bertram K, Woodrow G, Stephens RW (1990) Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class-2 plasmino-gen activator inhibitor. Proc Natl Acad Sci USA 87: 2230-2234
32. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Danø K, Appella E, Blasi F (1990) Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9: 467-474
33. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ (1990) Structure and function of lipopolysacchar-ide binding protein. Science 249: 1429-1434
34. Setyono-Han B, Sturzebecher J, Schmalix WA, Muehlenweg B, Sieuwerts AM, Timmermans M, Magdolen V, Schmitt M, Klijn JG, Foekens JA (2005) Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost 93: 779-786
35. Sidenius N, Blasi F (2003) The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22: 205-222
36. Skelly MM, Troy A, Duffy MJ, Mulcahy HE, Duggan C, Connell TG, O'Donoghue DP, Sheahan K (1997) Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res 3: 1837-1840
37. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K, Brünner N (1999) Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91: 869-874
38. Suzuki S, Hayashi Y, Wang Y, Nakamura T, Morita Y, Kawasaki K, Ohta K, Aoyama N, Kim SR, Itoh H, Kuroda Y, Doe WF (1998) Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut 43: 798-805
39. Tang H, Kerins DM, Hao Q, Inagami T, Vaughan DE (1998) The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem 273: 18268-18272
40. Vassalli JD, Baccino D, Belin D (1985) A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100: 86-92
41. Waltz DA, Chapman HA (1994) Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 269: 14746-14750
42. Wang JH, Manning BJ, Wu QD, Blankson S, Bouchier-Hayes D, Redmond HP (2003) Endotoxin/lipopolysaccharide activates NF-kappaB and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism. J Immunol 170: 795-804
43. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA (1996) Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555
44. Xue W, Mizukami I, Todd III RF, Petty HR (1997) Urokinase type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res 57: 1682-1689